PROK vs PSTV

ProKidney Corp. vs PLUS THERAPEUTICS, Inc. — Valuation Comparison 2026

PROK

Biotechnology
ProKidney Corp.
Quality
4.4
out of 10
Value Trap
6
SAFE
Price
$1.81
Last close
Models
9/13
Active
VS

PSTV

Biotechnology
PLUS THERAPEUTICS, Inc.
Quality
4.8
out of 10
Value Trap
36
LOW
Price
$6.43
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType PROK Fair ValuePROK Upside PSTV Fair ValuePSTV Upside
Bayesian DCF Intrinsic $0.67 -63.2% $2.02 -68.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.78 -57.1% $2.09 -67.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PROK vs PSTV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PROK vs PSTV — Which Stock Is More Undervalued?

PSTV scores higher with a 4.8/10 quality rating vs PROK's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ProKidney Corp. (PROK) and PLUS THERAPEUTICS, Inc. (PSTV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PROK currently trades at $1.81 with a QOC of 4.4/10, while PSTV trades at $6.43 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).